Stem cell-based drug could help treat chronic asthma

Associate Professor Chrishan Samuel.

A pre-clinical study, led by Associate Professor Chrishan Samuel, showing promise as a potential treatment for chronic asthma has been featured on Channel 9 News nationally, as well as Business Insider, PharmiWeb, MarketWatch, BenzingaBioPortfolio and several others. In mice, the study has shown that Cymerus™ - which uses induced pluripotent stem cell and mesenchymoangioblast-derived mesenchymal stem cells - calms the immune system, minimising the chances of having an attack and its severity. It has also been proven to improve airway constriction by 75 percent. “The (stem) cells are able to reduce the scar tissue and improve the function of the airways and lungs,” said Associate Professor Samuel. Researchers aim to begin a human trial within the next 12-24-months.